Media Summary: In this video, Tarek Mouhieddine, MD, Mount Sinai Medical Center, New York City, NY, provides insight into a study that aimed toΒ ... Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on results from a Phase I/II trialΒ ... Learn more about lung cancer at This animation provides an overview of immunotherapy forΒ ...

Pd 1 Plus Tim 3 - Detailed Analysis & Overview

In this video, Tarek Mouhieddine, MD, Mount Sinai Medical Center, New York City, NY, provides insight into a study that aimed toΒ ... Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on results from a Phase I/II trialΒ ... Learn more about lung cancer at This animation provides an overview of immunotherapy forΒ ... Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, explores the 24-month follow-up results from a Phase IΒ ... This Harvard Medical School Continuing Education video examines these key questions: How do immune checkpoint inhibitorsΒ ... In this week's VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the combination of Dr. Edward Garon explains the role of immunotherapy, PD-L1 and Visit for more. Dr Nanda (Dr Nanda talks to ecancertv at SABCS 2014 about the results of a phase IbΒ ... Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, discusses findings from the AMBER trialΒ ... Barbara Burtness, MD, Yale School of Medicine, New Haven, CT, discusses the findings from the population subgroup analysis ofΒ ...

Photo Gallery

PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab
Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma
Cancer Immune Checkpoint Inhibitors
What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more
𝗖𝗔𝗑 π—§π—œπ— -𝟯 π——π—˜π—™π—˜π—”π—§ 𝗣𝗗-𝟭 π—₯π—˜π—¦π—œπ—¦π—§π—”π—‘π—–π—˜ π—œπ—‘ π—–π—”π—‘π—–π—˜π—₯?
PD-1 and OX40: potential PDAC combination therapy
Explaining Immunotherapy, PD-L1 and PD-1
PD-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD–1
AMBER: anti-TIM3 antibody reverses T-cell exhaustion in NSCLC
View Detailed Profile
PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab

PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab

In this video, Tarek Mouhieddine, MD, Mount Sinai Medical Center, New York City, NY, provides insight into a study that aimed toΒ ...

Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors

Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on results from a Phase I/II trialΒ ...

Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers

Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers

Learn more about lung cancer at http://www.YouAndLungCancer.org This animation provides an overview of immunotherapy forΒ ...

Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma

Assessing LAG-3 & PD-1 inhibition with fianlimab & cemiplimab in advanced melanoma

Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, explores the 24-month follow-up results from a Phase IΒ ...

Cancer Immune Checkpoint Inhibitors

Cancer Immune Checkpoint Inhibitors

This Harvard Medical School Continuing Education video examines these key questions: How do immune checkpoint inhibitorsΒ ...

What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more

What’s new in checkpoint inhibition? LAG-3/PD-1 bispecifics, ADC combos, and more

In this week's VJOncology podcast, we bring you key updates on the evolving landscape of checkpoint inhibition beyond

𝗖𝗔𝗑 π—§π—œπ— -𝟯 π——π—˜π—™π—˜π—”π—§ 𝗣𝗗-𝟭 π—₯π—˜π—¦π—œπ—¦π—§π—”π—‘π—–π—˜ π—œπ—‘ π—–π—”π—‘π—–π—˜π—₯?

𝗖𝗔𝗑 π—§π—œπ— -𝟯 π——π—˜π—™π—˜π—”π—§ 𝗣𝗗-𝟭 π—₯π—˜π—¦π—œπ—¦π—§π—”π—‘π—–π—˜ π—œπ—‘ π—–π—”π—‘π—–π—˜π—₯?

Explore

PD-1 and OX40: potential PDAC combination therapy

PD-1 and OX40: potential PDAC combination therapy

Cassian Yee, MD, MD Anderson Cancer Center, The University of Texas, Houston, TX, discusses the combination of

Explaining Immunotherapy, PD-L1 and PD-1

Explaining Immunotherapy, PD-L1 and PD-1

Dr. Edward Garon explains the role of immunotherapy, PD-L1 and

PD-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer

PD-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer

Visit http://www.ecancer.org for more. Dr Nanda (Dr Nanda talks to ecancertv at SABCS 2014 about the results of a phase IbΒ ...

Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD–1

Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD–1

10

AMBER: anti-TIM3 antibody reverses T-cell exhaustion in NSCLC

AMBER: anti-TIM3 antibody reverses T-cell exhaustion in NSCLC

Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, discusses findings from the AMBER trialΒ ...

Pembrolizumab plus CRT shows long-term benefit in PD-L1-rich HNSCC: KEYNOTE-412

Pembrolizumab plus CRT shows long-term benefit in PD-L1-rich HNSCC: KEYNOTE-412

Barbara Burtness, MD, Yale School of Medicine, New Haven, CT, discusses the findings from the population subgroup analysis ofΒ ...